Viral particle, and preparation method therefor and use thereof

By introducing T cell activation signal molecules on the surface of the virus particles and mutating glycoproteins, the problem of low efficiency in target activation and transduction of T cells is solved, the killing efficiency of CAR-T cells and the expression of CAR molecule are improved, and more efficient T cell therapy is achieved.

WO2025149068A1 Publication Date: 2025-07-17SHENZHEN GENOCURY BIOTECH CO LTD
9 Cites 3 Cited by

Patent Information

Application Number
PCT/CN2025/071920
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-10
Filing Date
2025-01-10
Publication Date
2025-07-17

AI Technical Summary

Technical Problem

In the prior art, it is still a problem to improve the efficiency and specificity of targeted activation and transduction of T cells, especially non-activated T cells, and to improve the membrane-output expression efficiency and killing efficiency of CAR molecules in T cells in CAR-T cell therapy.

Method used

A viral particle is designed with T cell activation primary signaling molecules and secondary signaling molecules, such as anti-CD3 and anti-CD28 antibodies, which weaken the binding ability to LDL-R by mutant glycoproteins and enhance the antagonism of complement to improve the targeting and transduction efficiency of viral particles.

Benefits of technology

The targeted activation and transduction ability of virus particles to non-activated T cells is significantly improved, and the membrane expression efficiency of CAR molecules in T cells and the killing efficiency of prepared CAR-T cells is enhanced.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A viral particle. The surface of the viral particle comprises a T cell activation primary signaling molecule and a T cell activation secondary signaling molecule; the envelope glycoprotein of the viral particle is subjected to a first mutation, so that the receptor binding ability of the viral glycoprotein is weakened or lost with respect to its receptor binding ability before the first mutation; and the envelope glycoprotein of the viral particle can also be subjected to a second mutation, so that the viral particle has enhanced resistance to complement-mediated inactivation or is not subjected to complement-mediated inactivation. The viral particle has improved specificity for targeted activation, stimulation and transduction of non-activated T cells, and is thus more applicable for the preparation of CAR-T cells in subjects.
Need to check novelty before this filing date? Find Prior Art